3 Generic liraglutide, approved in late 2024, has begun to pull that older drug's price down
This regulatory approval, announced this week, allows for a more cost-effective alternative to branded weight-loss medications that have faced unprecedented global demand and persistent supply chain constraints
However, the existing body of research suggests that DSIP could be a promising tool in the treatment of sleep disorders, chronic pain, and neurodegenerative diseases.
data indicate that approximately 90% of adults meet criteria for a CKM stage, with higher prevalence in older adults and in men, and a projected further increase due to the ongoing epidemics of obesity and diabetes [147]
Guan X, Hoffman B, Dwivedi C, Matthees DP